Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...

Discover the latest research on Ozempic and other GLP-1 medications, including potential uses in treating Alzheimer's and opioid and alcohol use disorders.

The full-year cost of care for U.S. patients with obesity two years after starting on Novo Nordisk’s Wegovy or similar GLP-1 ...

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience has reported promising results from its diabetes animal study, revealing ...

Lexaria Bioscience (LEXX) received partial 12-week blood sugar results from the recently completed animal study WEIGHT-A24-1. The company said, ...

Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...

In announcing the results, Novo Nordisk said Rybelsus, an oral glucagon-like peptide-1 (GLP-1) receptor agonist already ...

When you're taking GLP-1 medications for weight loss, it's easy for nutrition to get overlooked because while semaglutide ...

Bernstein said Novo Nordisk (NVO) study results that showed certain Rybelsus users had a 14% risk reduction for major ...

If you’ve listened to any weight-loss podcasts or watched the news in the past year, you’ve probably heard of the new drugs: ...

Novo Nordisk NVO announced positive top-line data from a late-stage cardiovascular outcomes study that evaluated its oral ...